It will go up when it suits the institutions and the funds.
To me it defies logic that a company who is sitting on multiple drug device delivery contracts with two of them having an Asthma indication, whose market potential is 15-25 million severe Asthma suffers worldwide, it's stock is selling for 17.5c AUD or .74c USD.
Of course the bashers never mention anything about the scope of those contracts. What they mention is that UNS is a syringe company that can't sell a syringe. Clever bit of obfuscation.
UNS Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
